investors - International Biopharmaceutical Industry

news

Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan

Biogen’s drug for Alzheimer’s disease, once considered a blockbuster-in-waiting, has run into so many obstacles since gaining approval last June that the company is n...

9 May 2022 news Aduhelm | Alzheimer

Continue Reading →

news

J&J cuts COVID vaccine sales forecasts, citing high supplies and lagging demand

Dive Brief: Johnson & Johnson is lowering its forecast for COVID-19 vaccine sales, announcing Tuesday it will has suspended its guidance of $3 billion to $3.5 ...

25 April 2022 news billion | COVID

Continue Reading →

news

Bluebird’s CFO resigns as cash woes raise doubts about its future

Dive Brief: Bluebird bio's chief financial officer Gina Consylman will resign amid growing concerns the company needs to raise additional money to survive more tha...

14 March 2022 news Bluebird | financial

Continue Reading →

news

Allakos shares plunge as company’s top drug falls short in studies

While Allakos isn't giving up on its lead drug, the study results clearly disappointed investors. There's some kind of "disconnect" in the study results, Maury Raycr...

7 January 2022 news Allakos | investors

Continue Reading →

news

ANTABIO Completes € 12.5M Series A

New investors Omnes, BNP Paribas Développement and Sham Innovation Santé invest an additional €5.2M on top of the €7.3M first closing announced in October 2017 Antab...

13 July 2018 news 12.5m | ANTABIO

Continue Reading →

Current Edition

Upcoming Events

Advertisement

Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan

J&J cuts COVID vaccine sales forecasts, citing high supplies and lagging demand

Bluebird’s CFO resigns as cash woes raise doubts about its future

Allakos shares plunge as company’s top drug falls short in studies

ANTABIO Completes € 12.5M Series A

International Biopharmaceutical Industry